Find the products and resources you are looking for!
Get in touch!
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec Ltd.
Almac House, Church Lane
Bisley, Surrey GU24 9DR
Phone: +44 1483 799 800
Fax: +44 1483 799 811
E-Mail: macs@miltenyibiotec.co.uk
Web: www.miltenyibiotec.com
For immediate technical support, use our live chat.
Connect with usMiltenyi Biotec distribution:
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Our local employees are always happy to answer your questions. Highly trained and experienced teams in your country can provide quick, helpful, and comprehensive support.
Miltenyi Biotec Ltd.
Almac House, Church Lane
Bisley, Surrey GU24 9DR
United Kingdom
Phone: +44 1483 799 800
Fax: +44 1483 799 811
E-Mail: macs@miltenyibiotec.co.uk
Web: www.miltenyibiotec.com
For immediate technical support, use our live chat. Connect with us
As a global market leader with numerous subsidiaries and distributors, Miltenyi Biotec is committed to providing our customers around the world with the highest quality products. In addition to direct selling in more than 20 countries in North America, Europe and Asia/Pacific, Miltenyi Biotec also provides support for our customers through an extensive distributor network covering dozens of additional countries.
Cookie Settings
We use cookies to provide the best possible website experience for you. This includes cookies that are technically required to ensure a proper functioning of the website, as well as cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for displaying personalized content. You are free to choose the categories you would like to permit. Please note that depending on your settings, the full functionality of the website may no longer be available. Further information can be found in our Privacy Statement and Cookie Statement.
Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. |
A: | B: |
Before separation |
ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. | ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. |
Lineage-negative cells |
ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. | ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. |
Isolated CD294 (CRTH2)+ ILC2 |
ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. | ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. |
Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. |
A: | B: |
Before separation |
ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. | ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. |
Lineage-negative cells |
ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. | ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. |
Isolated CD294 (CRTH2)+ ILC2 |
ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. | ILC2 Isolation Kit, humanFigure 1Type 2 innate lymphoid cells (ILC2) were isolated from peripheral blood mononuclear cells by using the ILC2 Isolation Kit, two LS and two MS Columns, as well as a MidiMACS ™ Separator and a MiniMACS ™ Separator. The cells were fluorescently stained with CD45-VioBlue ® and lineage markers (CD2, CD3, CD14, CD16, CD123, CD235a (Glycophorin A) conjugated to FITC, CD19 and CD56 conjugated to VioBright ™ FITC), and CD294 (CRTH2)-PE (A) or CD161-PE-Vio ® 770 and CD127-APC (B) and analyzed by flow cytometry using the MACSQuant ® Analyzer. Cell debris and dead cells were excluded from analysis based on scatter signals, CD45, and propidium iodide fluorescence. |
Seems like you are coming from USA!
Do you want to visit our website in your country?
Copyright © 2022 Miltenyi Biotec and/or its affiliates. All rights reserved.